(Q35000135)

5 August 2017

title

Clofarabine: emerging role in leukemias (English)

1 reference

5 August 2017

2

Hagop Kantarjian

1 reference

5 August 2017

3

Gautam Borthakur

1 reference

5 August 2017

Keeran Sampat

1

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Expert Opinion on Investigational Drugs

5 August 2017

published in

1 reference

5 August 2017

volume

18

1 reference

5 August 2017

issue

10

1 reference

5 August 2017

page(s)

1559-1564

1 reference

Clofarabine: past, present, and future

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543780903173222

Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903173222

Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903173222

Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903173222

Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)adenine (Cl-F-ara-A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903173222

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903173222

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903173222

Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903173222

Biochemical modulation of cytarabine triphosphate by clofarabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903173222

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903173222

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903173222

Clofarabine combinations as acute myeloid leukemia salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903173222

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903173222

10.1517/13543780903173222

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference